Details

Autor(en) / Beteiligte

• Nagano, Hiroaki
• Ichinoe, Akimasa
• Hashimoto, Kazunori

Titel

2022-RA-435-ESGO Significance of the peritoneal washing cytology as a predictive factor of the long-term benefit of secondary debulking surgery for ovarian cancer

Ist Teil von

• International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A232-A233

Ort / Verlag

Oxford: BMJ Publishing Group Ltd

Erscheinungsjahr

2022

Link zum Volltext

Beschreibungen/Notizen

• Introduction/BackgroundThe role of surgery in ovarian cancer recurrence is still debated. Previous studies indicate that only complete resection is associated with long-term benefits. Therefore, this study aimed to determine other clinical factors of ovarian cancer relapse in patients who might obtain survival benefits from secondary debulking surgery (SDS).MethodologyWe retrospectively examined the clinical records of patients with ovarian high-grade serous carcinoma (HGSC) who underwent SDS for intraperitoneal recurrent disease. Platinum-free interval (PFI), residual tumor size at initial surgery and SDS, peritoneal washing cytology (PWC) at SDS, and performance-status (PS) score before SDS were investigated. All patients underwent assessment with computed tomography prior to surgery and during follow-up. Patients with short post-SDS follow-up were excluded.ResultsFrom 2007 to 2018, 59 patients with ovarian, fallopian, or peritoneal HGSC were treated at our institute. Among them, 35 patients experienced relapse with intraperitoneal disease. Fourteen patients underwent SDS. One patient was excluded because of a short follow-up. The median patient age was 70 years, and the median PFI was 36 months. Complete resection at the initial surgery and a PS score of 0 were confirmed in 11 and 10 patients, respectively. Ascites was not observed in any patient. Complete resection at SDS was performed in 12 patients. PWC was negative in 9 patients and positive in 4 patients. All the cytology-positive patients experienced intraperitoneal recurrence after SDS, but none of the cytology-negative patients experienced recurrence during follow-up (median 78 months). The association between PWC and recurrence after SDS was significant (p = 0.0014, Fisher’s exact test).Abstract 2022-RA-435-ESGO Table 1Summary of patient data No Age FIGO stage Initial surgery/residual PFI (month) Prior chemo PS Acsites SDS/residual Washing cytology Intraperitoneal relapse after SDS Outcome Follow up (month) 1 74 IVB IDS/0 mm 32 no 0 no 0 mm negative no NED 82 2 72 IIIC IDS/<10 mm 6 yes 1 no <10 mm positive yes DFD 16 3 82 IIIC PDS/0 mm 17 no 1 no 0 mm positive yes DFD 40 4 65 IIIC PDS/0 mm 81 yes 0 no 0 mm negative no NED 20** 5 66 IC PDS/0 mm 60 no 0 no 0 mm negative no LN meta/NED* 89 6 69 IIIC PDS/<10 mm 37 yes 0 no 0 mm negative no NED* 84 7 70 IIIB PDS/0 mm 44 no 1 no 0 mm positive yes DFD 36 8 53 IC PDS/0 mm 42 yes 0 no 0 mm negative no NED 108 9 73 IIIC IDS/0 mm 27 yes 0 no 0 mm negative no DFOD 78 10 72 IIIC PDS/0 mm 36 yes 0 no 0 mm negative no Brain meta/DFD 43 11 77 IIC PDS/0 mm 63 no 0 no 0 mm negative no DFOD 58 12 57 IIIC IDS/0 mm 27 yes 0 no 0 mm positive yes DFD 17 13 48 IIIC PDS/0 mm 23 yes 0 no 0 mm negative no NED 44** ConclusionPWC, in addition to complete resection, seems a notable predictor of the long-term benefit of SDS for patients who experience ovarian cancer recurrence.